Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2006 1
2007 1
2008 1
2010 1
2012 1
2013 3
2014 1
2015 3
2016 2
2017 1
2018 1
2019 1
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6.
Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ. Takahashi PY, et al. Pharmgenomics Pers Med. 2017 Feb 14;10:39-47. doi: 10.2147/PGPM.S114211. eCollection 2017. Pharmgenomics Pers Med. 2017. PMID: 28243137 Free PMC article.
BACKGROUND: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and other environmental exposures, but it is unclear whether the CYP2D6 phenotype is associated with adverse health outcomes. ...CONCLUSIO …
BACKGROUND: Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of clinically used drugs and o …
Applications of CYP450 testing in the clinical setting.
Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Samer CF, et al. Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5. Mol Diagn Ther. 2013. PMID: 23588782 Free PMC article. Review.
CYP2D6 PM phenotype has been associated with an increased risk of toxicity of metoprolol, timolol, carvedilol and propafenone. ...CYP2C19 is involved in the metabolism of several antidepressants. As a result of an increased risk of advers
CYP2D6 PM phenotype has been associated with an increased risk of toxicity of metoprolol, timolol, carvedilol and propa
[Pharmacoresistance to psychotropic drugs in children and adolescents: Pharmacogenetic anomalies of cytochrome P450 2D6].
David A, Fernandez A, Menard ML, Dor E, Leali G, Maria F, Cruzel C, Askenazy F, Verstuyft C, Thümmler S. David A, et al. Encephale. 2021 Jun;47(3):227-234. doi: 10.1016/j.encep.2020.09.010. Epub 2021 Feb 4. Encephale. 2021. PMID: 33551122 French.
OBJECTIVES: Some patients in child and adolescent psychiatry present resistance to psychotropic drugs, often resulting in polytherapy, an increased risk of adverse events, and more frequent and longer hospitalisation. Psychotropic drugs are mainly metabolised …
OBJECTIVES: Some patients in child and adolescent psychiatry present resistance to psychotropic drugs, often resulting in polytherapy, an …
Complexities of CYP2D6 gene analysis and interpretation.
Gaedigk A. Gaedigk A. Int Rev Psychiatry. 2013 Oct;25(5):534-53. doi: 10.3109/09540261.2013.825581. Int Rev Psychiatry. 2013. PMID: 24151800 Review.
Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and bioactivation of about 25% of clinically used drugs including many antidepressants, antipsychotics and opioids. CYP2D6 activity is highly variably ranging from no
Cytochrome P450 2D6 (CYP2D6) plays an important role in the metabolism and bioactivation of about 25% of
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, Truong TM, van Wijk XMR, Yeo KJ, Malec M, Ratain MJ, O'Donnell PH. Reizine N, et al. Oncologist. 2021 Nov;26(11):e2042-e2052. doi: 10.1002/onco.13953. Epub 2021 Sep 19. Oncologist. 2021. PMID: 34423496 Free PMC article.
Patients with intermediate and/or poor CYP2D6 metabolizer status do not adequately convert codeine, tramadol, and hydrocodone into active compounds, with resulting increased risk of inadequate analgesia. This study showed that patients with cancer freq …
Patients with intermediate and/or poor CYP2D6 metabolizer status do not adequately convert codeine, tramadol, and hydrocodone …
Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.
Söderberg Löfdal KC, Andersson ML, Gustafsson LL. Söderberg Löfdal KC, et al. Drugs. 2013 May;73(6):533-43. doi: 10.1007/s40265-013-0036-0. Drugs. 2013. PMID: 23605691 Review.
The bioavailability is higher than for morphine and less variable. Oxycodone is primarily metabolized in the liver by the cytochrome P450 (CYP) enzymes with CYP3A as the major metabolic pathway and CYP2D6 as the minor metabolic pathway to …
The bioavailability is higher than for morphine and less variable. Oxycodone is primarily metabolized in the liver by the cytochro
Pharmacogenetics of opioid response.
Somogyi AA, Coller JK, Barratt DT. Somogyi AA, et al. Clin Pharmacol Ther. 2015 Feb;97(2):125-7. doi: 10.1002/cpt.23. Epub 2014 Dec 9. Clin Pharmacol Ther. 2015. PMID: 25670515
For opioids requiring CYP2D6 O-demethylation to active metabolites, poor metabolizers have reduced metabolite formation and minimal pain reduction. Clinically, this has only reliably been shown for tramadol. Ultra-rapid metabolizers have an increased
For opioids requiring CYP2D6 O-demethylation to active metabolites, poor metabolizers have reduced metabolite formation and mi …
The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC. Mulder H, et al. Pharmacoepidemiol Drug Saf. 2006 Feb;15(2):107-14. doi: 10.1002/pds.1173. Pharmacoepidemiol Drug Saf. 2006. PMID: 16294366
PURPOSE: This retrospective follow-up study investigates whether cytochrome P450-2D6 (CYP2D6) genotype explains variability in plasma concentrations of psychotropic drugs in daily psychiatric practice. ...In addition, the risk of a plasma concen …
PURPOSE: This retrospective follow-up study investigates whether cytochrome P450-2D6 (CYP2D6) genotype explains …
Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K. Saarikoski T, et al. Eur J Clin Pharmacol. 2015 Mar;71(3):321-7. doi: 10.1007/s00228-014-1799-2. Epub 2015 Jan 6. Eur J Clin Pharmacol. 2015. PMID: 25560051 Clinical Trial.
Its primary active metabolite is O-desmethyltramadol (M1), which is mainly accountable for the mu-opioid receptor-related analgesic effect. Tramadol is metabolized to M1 mainly by cytochrome P450 (CYP)2D6 enzyme and to other metabolites by CYP3A4 and C …
Its primary active metabolite is O-desmethyltramadol (M1), which is mainly accountable for the mu-opioid receptor-related analgesic effect. …
The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK, Bråten LS, Haslemo T, Molden E. Kringen MK, et al. J Clin Psychopharmacol. 2020 Mar/Apr;40(2):137-144. doi: 10.1097/JCP.0000000000001174. J Clin Psychopharmacol. 2020. PMID: 32134850
The study population was divided into different phenotype subgroups according to the combinations of CYP2D6/CYP2C19 phenotypes; intermediate metabolizers (IMs), poor metabolizers (PMs) and ultrarapid metabolizers, and compared using combined nor …
The study population was divided into different phenotype subgroups according to the combinations of CYP2D6/CYP2C19 phenotypes; inter …
19 results